A Comparative Evaluation of Tromexan and Dicumarol in the Treatment of Thromboembolic Conditions—Based on Experience with 514 Patients
A Report of the Committee on Anticoagulants of the American Heart Association
An evaluation of the comparative actions of Tromexan and dicumarol is herein reported. Five hundred fourteen patients were studied; a total experience of 6,642 days of Tromexan therapy and 5,006 days of dicumarol therapy were reviewed and analyzed. Previous reports of the more rapid initial prolongation of the prothrombin times and more rapid return to normal following cessation of therapy with Tromexan were confirmed. During adequate therapy the protection against thromboembolism was approximately equal for the two drugs. In other respects and with minor variations Tromexan and dicumarol were found to be quite comparable. The general advantages of anticoagulant therapy in the prevention of deaths and thromboembolic complications in myocardial infarction were comfirmed.
- © 1952 American Heart Association, Inc.